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Purpose: Prostate-specific antigen (PSA) response rate (>50% PSA decline in pretreatment PSA following chemotherapy) carries a 
significant survival advantage in castration-resistant prostate cancer (CRPC). We compared PSA response rates in first-, second- and 
third-line chemotherapy after failure of previous chemotherapy according to chemotherapeutic agents.
Methods: We retrospectively evaluated the oncological outcomes and PSA response rates of 384 patients with CRPC, who were treated 
with chemotherapy and had histologically proven adenocarcinoma of the prostate with failure after androgen ablation therapy between 
1991 and 2012, at Asan Medical Center.
Results: In 384 eligible patients, the median age was 67.5 years. The median pretreatment PSA and initial Gleason scores at baseline 
were 92.4 ng/mL (range, 2.0 to 6,370 ng/mL) and 9 (range, 6 to 10), respectively. The time from first diagnosis of prostate cancer to CRPC 
was 23 months (range, 1 to 164 months). As first-line chemotherapy, 245 patients (63.8%) received estramustine, 91 (23.7%) received 
docetaxel, and 39 (10.2%) received mitoxantrone. The PSA response rates were 39.6%, 51.6%, and 46.2%, respectively. Of 169 patients 
with second-line chemotherapy, estramustine was 15 (8.9%), docetaxel was 84 (49.7%), and mitoxantrone was 52 (30.8%). PSA response 
rates were 57.1%, 52%, and 28.0%, respectively. Of 81 patients with third-line chemotherapy, estramustine was 18 (22.2%), docetaxel 
was 16 (19.8%), and mitoxantrone was 28 (34.6%). The PSA response rates were 41.2%, 53.8%, and 11.1%, respectively. Declines in serum 
PSA levels of at least 50% occurred more frequently after treatment with docetaxel than with other chemo-agents regardless of second- 
and third-line chemotherapy. Even in third-line chemothrapy, docetaxel maintained the PSA response rate, whereas the PSA response 
rate of other agents, including mitoxantrone, decreased in patients in whom prior therapy failed.
Conclusions: Docetacel was the most effective chemotherapeutic agent in second- and third-line trials of chemotherapy in Korean 
CRPC patients. Although docetaxel is not used as first-line chemotherapy, and new agents are not available for therapy in CRPC patients, 
we can consider docetaxel a second- or third-line chemotherapy in CRPC. 
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INTRODUCTION 
Prostate cancer is the most common cancer in men in the 
United States and the fifth most common cancer in men in 
Korea [1]. Androgen deprivation therapy (ADT) remains the 
main treatment for metastatic, hormone-sensitive prostate 
cancer. Although ADT is effective in lowering PSA in most 
men, the therapeutic response will eventually wane, and the 
disease will eventually progress. For many years, development 
of new therapies and new treatment strategies emerged slow-
ly for prostate cancer in general and for castration-resistant 
prostate cancer (CRPC) in particular. However, in recent years 
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that has changed with the emergence of various new agents 
that access several different mechanistic disease pathways. 
Additional drugs have been approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of CRPC in the 
past three years than in the prior three decades. These new 
treatment options include, among others, a new cytotoxic 
agent, immunotherapy, and androgen receptor-signaling 
inhibitors. The newest agents of U.S. FDA approval of were 
enzalutamide [2], abiraterone [3], and cabazitaxel [4]. 
 Although many new drugs are on the verge of approval, 
based on the results of recently reported randomized tri-
als, many countries still use docetaxel-based chemotherapy 
because of socio-economic issues. Docetaxel-based chemo-
therapy is currently the treatment of choice in patients with 
CRPC because it prolongs survival rates compared with the 
previously standard mitoxantrone therapy [5,6]. Several re-
cent studies have demonstrated the feasibility and activity of 
a single docetaxel rechallenge, thus providing an additional 
opportunity in clinical practice for treatment of docetaxel-
sensitive CRPC patients [7-9]. Currently, in Korea many che-
motherapy agents are also administrated to CRPC patients, 
but only a few reports of clinical outcomes of chemotherapy 
have been published, and new chemotherapy agents are re-
stricted because of the parameters of the national insurance. 
Therefore, we undertook this study to investigate the outcomes 
of chemotherapy in the treatment of CRPC in real life practice 
in Korean patients. We compared the feasibility and efficacy 
of chemotherapeutic agents in docetaxel-sensitive CRPC pa-
tients in first-, second-, and third-line settings.
MATERIALS AND METHODS 
1. Patients 
We retrospectively evaluated the oncological outcomes and 
PSA response rates in 412 patients with CRPC, who were treat-
ed with chemotherapy between 1991 and 2012, at Asan Medi-
cal Center. Patient records were retrospectively reviewed to 
determine base-line characteristics and clinical efficacy. The 
sample comprised 384 eligible patients with histologically 
proven adenocarcinoma of the prostate and documented dis-
ease progression (documented locoregional or distant metas-
tases and/or PSA increase) after failure of androgen ablation 
therapy or second hormonal treatment. Progressive disease 
was defined by an increase in PSA levels as determined by 2 
consecutive measurements at least 2 weeks apart, an increase 
in the size of a measurable lesion by computed tomography 
or any newly developed bony metastasis with hot uptake by 
bone scan. To investigate differences in prior chemotherapy, 
patients were classified into three groups: the first-line group 
consisted of patients who had undergone no prior chemo-
therapy; the second-line group had undergone first-line che-
motherapy; and the third-line group had undergone previous 
second-line chemotherapy. The first-line therapy for each 
CRPC patient in this study was determined at the physicians’ 
discretion, based on cancer-related symptoms, rising PSA, 
extent of metastasis and performance status. The second- 
and third-line therapy was determined based on treatment 
response to and progression on prior chemotherapy treat-
ment as well as drug toxicity. Patients treated with androgen-
deprivation therapy during the interval from prior chemo-
therapy to next chemotherapy were included and patients 
treated with new agents in clinical trials were excluded from 
this study.
2. PSA response and overall survival
The criteria used for determining responses were based on 
the guidelines of the PSA working group [10]. A PSA decline 
of 50%, confirmed by a second evaluation at least three weeks 
later, was considered a PSA response with no evidence of 
disease progression in imaging in the available patients and 
progression was defined as the increase in PSA. Baseline PSA 
was defined as the PSA value obtained within a two-week 
period prior to starting the chemotherapy in the study. Be-
cause the chemotherapy agents mainly used in this study 
were estramustine-based chemotherapy, docetaxel and mi-
toxantrone, our analysis focused on these agents. The group 
of estramustine-based chemotherapy (estramustine only, 
estramustine+etoposide, estramustine+hormone therapy, 
etc.) was considered the estramustine group. However, estra-
mustine combined with docetaxel group was considered the 
docetaxel group in this study. Overall survival was defined as 
the time between the administration of the first chemothera-
py and death. 
3. Statistical analysis
The major statistical endpoints of this study consisted of PSA 
response and overall survival. We also investigated differ-
ences between these endpoints in first, second- and third-
line groups. Overall survival curves were produced using the 
Kaplan-Meier method. Differences between the first-, sec-
ond- and third-line groups were compared using the log-rank 
test. The T test (or Mann-Whitney test fornon-parametric 
variables) was used for continuous variables. The chi-square 
(or Fisher exact test for nonparametric variables) was used for 
categorical variables. P-values < 0.05 (2-sided) were consid-
ered statistically significant, and confidence intervals were set 
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at the 95% level. All analyses were performed using the IBM 
SPSS ver. 20.0 (IBM Co., Armonk, NY, USA).
RESULTS
1. Patient characteristics
A total of 412 patients were enrolled between October 1991 
and January 2012. Twenty-eight patients did not meet the 
study`s criteria: 16 had missing documentation of PSA levels; 
7 had inadequate baseline laboratory studies; and 5 were 
eliminated for miscellaneous reasons. The baseline charac-
teristics of the 384 patients are listed in Table 1. Of the 384 
study patients, the median age was 68.0 years (range, 44 to 
87 years). The median pretreatment PSA and initial Gleason 
score at baseline in the overall population were 96 ng/mL 
(range, 2 to 6,370 ng/mL) and 9 (range, 6 to 10), respectively. 
The time from first diagnosis of prostate cancer to CRPC was 
22 months (range, 0 to 165 months). In terms of metastases, 
76 patients (25.0%) had visceral metastasis and most other 
patients had bone or lymph node metastasis. The compari-
son analysis among baseline tumor characteristics according 
to each chemotherapy-line showed no significant difference. 
 The number of eligible patients was divided into two groups, 
based on the year 2004 (i.e., before and after the docetaxel 
era). The patients’ characteristics after 2004, in the docetaxel 
era, were similar to those before the docetaxel era, except for 
baseline alkaline phosphatase levels, significant pain, and 
the time from initial diagnosis to first-line chemotherapy 
(Table 1). Although initial PSA levels of the patients treated 
before the doxetaxel era tended to be high compared with 
those of patients treated after the docetaxel era, there was no 
significant difference. At initial chemotherapy, of the 384 pa-
tients, 245 (63.8%) received estramustine, 91 (23.7%) received 
docetaxel, and 39 (10.2%) received mitoxantrone. Of the 
169 patients with second chemotherapy, 88 (42%) received 
docetaxel, 51 (25%) received mitoxantrone, and 21 (10%) re-
ceived estramustine. Of 84 patients with third-line chemother-
apy, 28 (34.6%) received mitoxantrone, 18 (22.2%) received 
estramutine, and 16 (19.8%) received docetaxel (Table 2).
2. Serum PSA response
Overall PSA responses ( > 50% PSA decline in pretreatment 
PSA following chemotherapy) were as follows: 43.5% at first-
line chemotherapy, 42.4% at second-line chemotherapy, and 
Table 1. Baseline characteristics of the patients
Characteristic Total patient Nondocetaxel era (<2004 yr) Docetaxel era (≥2004 yr)
No. 384 94 290
Age (yr) 68 (44–87) 69 (44–87) 67.5 (45–87)
PSA at initial diagnosis (ng/mL) 96 (2–6,370) 89 (4–4,830) 94.6 (2.0–6,370.0)
PSA at CRPC (ng/mL) 28.2 (0.2–3707.0) 41.4 (0.6–3707.0) 24.2 (0.2–2510.0)
Baseline Hb (mg/dL) 11.6 (7.1–15.8) 11.3 (7.1–15.2) 11.9 (7.4–15.8)
Baseline ALP (IU/L) 124 (41–7,604) 167.5 (54.0–7,604.0) 106 (41–1,160)
Gleason score
≤6 10 (3) 6 (6) 4 (1.4)
7 58 (15) 14 (15) 44 (15)
≥8 316 (82) 74 (79) 242 (83)
Disease extension at baseline
Bone metastases 308 (85.4) 77 (82.1) 251 (86.7)
Visceral metastases 76 (25.0) 26 (29.3) 70 (24.3)
ECOG 1 (0–3) 1 (0–3) 1 (0–3)
Significant pain 161 (42) 22 (23) 139 (48)
Period from diagnosis to chemotherapy 22 (0–165) 17 (0–103) 26 (0–165)
Values are presented as median (range) or number (%).
PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; Hb, hemoglobin; ALP, alkaline phosphatase; ECOG, Eastern Cooperative On-
cology Group.
Table 2. The distributions of chemotherapy agents in all pa-
tients
Variable
First-line  
therapy
Second-line 
therapy
Third-line  
therapy
Estramustine 245 (63.8) 15 (8.9) 18 (22.2)
Docetaxel 91 (23.7) 84 (49.7) 16 (19.8)
Mitoxantrone 39 (10.2) 52 (30.8) 28 (34.6)
Vincristine + cyclo-
phosphamide
5 (1.3) 13 (7.7) 12 (14.3)
Etc. 4 (1.0) 5 (2.9) 10 (11.9)
Total 384 (100) 169 (100) 84 (100)
Values are presented as number (%).
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32.1% at third-line chemotherapy (Fig. 1). Declines in serum 
PSA levels of at least 50% occurred more frequently after treat-
ment with docetaxel and estramustine than after treatment 
with mitoxantrone but this was not significant (P = 0.615) 
at first line chemotherapy. However, at second- and third-
line chemotherapy, PSA responses were significantly more 
frequently demonstrated in the docetaxel and estramustine 
groups compared with the mitoxantrone group (second, P =  
0.017; third, P = 0.010). When PSA responses were analyzed 
based on the year 2004, there was no statistically significant 
difference (first, 47.9% vs. 42.1%, P = 0.193; second, 26.9% vs. 
45.3%, P = 0.062; third, 33.3% vs. 31.9%, P = 0.631). 
3. Survival
Median overall survival was 19.0 months (range, 1 to 99 
months). The overall survival curve is presented in Fig. 2A. 
According to first-line and third-line chemotherapy agents, 
there were no differences in median survival (P = 0.365 and 
P = 0.329). However, according to second-line chemotherapy 
agents, the docetaxel and estramustine group had longer me-
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Fig. 2. Kaplan-Meier estimates of overall survival among men with androgen-independent prostate cancer treated with chemother-
apy agents. (A) Median overall survival was 19.0 months in total eligible patients. (B–D) According to first and third-line chemothera-
py agents, there were no differences in median survival by the log rank test (P=0.365 and P=0.329). However, with second-line che-
motherapy agents, docetaxel and estramustine group were longer in median survival than mitoxantrone group (P=0.003). HR, haz-
ard ratio; CI, confidence interval.
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dian survival than the mitoxantrone group did (median value, 
30 months vs. 21 months vs. 19 months, P=0.003) (Fig. 2B–D). 
When overall survivor rates were analyzed based on the year 
2004, the patients after docetaxel era (after 2004) showed sig-
nificantly longer overall survival (median value, 14 months vs. 
20 months; P = 0.001; hazard ratio [HR], 0.65; 95% confidence 
interval [CI], 0.52 to 0.83) (Fig. 3A). The median overall survival 
was 31.5 months in patients treated with docetaxel chemo-
therapy in second-line chemotherapy and 19.5 months in 
patients treated with docetaxel chemotherapy in first-line 
chemotherapy (P = 0.002) (Fig. 3B). The corresponding haz-
ard ratio for death was 0.60 (95% CI, 0.43 to 0.83). 
DISCUSSION 
In the last three decades, various kinds of chemotherapies for 
CRPC have been tried in order to improve understanding of 
the pathogenesis of CRPC. To assess the treatment outcomes 
of new agents in CRPC, the Response Evaluation Criteria in 
Solid Tumors (RECIST) group recommended both tumor 
shrinkage (objective response) and disease progression as 
useful endpoints in clinical trials [11]. A key question consid-
ered by the RECIST Working Group in developing RECIST 1.1 
was whether it was appropriate to move from an anatomic 
unidimensional assessment of tumor burden to either a volu-
metric anatomical assessment or a functional assessment 
with positron emission tomography or magnetic resonance 
imaging. However, 80% to 90% of CRPC patients do not have 
bidimensionally measurable disease. The Prostate Cancer 
Working Group 2 recommended that using the same meth-
ods used at enrolment, investigators should measure early-
response outcomes by the changes in the individual disease 
manifestations present initially for both cytotoxic and noncy-
totoxic drugs [12]. In this study, to evaluate therapeutic out-
comes, PSA response rates (>50% PSA decline in pretreatment 
PSA following chemotherapy) were used. Because many cli-
nicians were involved in this study, a long-period retrospec-
tive study was designed, and various chemotherapy agents 
were used, PSA response rates as markers of chemotherapy 
response could be applied to all cases objectively.
 Many contemporary studies have used PSA as a marker 
of response, even though there is no consensus about the 
magnitude and duration of decline in PSA levels. Although 
PSA is used as a rapid screening tool to test new agents for 
activity, there is conflicting evidence about the role of PSA 
as a response marker. However, it has been reproducibly 
shown that > 50% PSA decline in pretreatment PSA follow-
ing therapy had a significant advantage in survival [13]. An 
improved PSA response was also associated with prolonged 
survival in the TAX 327 study, with a median survival of 33 
months when the PSA was normalized ( < 4 ng/mL) versus 
15.8 months for an abnormal PSA. This study also showed 
that a PSA response was not a surrogate marker for survival. 
Even though the same PSA response rate was found in both 
docetaxel arms (45%), improved survival only occurred with 
a regime of docetaxel three times a week. According to the 
most recent evaluation of the TAX 327 and SWOG 99-16 stud-
ies, a PSA decrease of > 30% is associated with a significant 
survival benefit [14,15]. In this study, regardless of first-line 
chemotherapy agents, the overall survival rate significantly 
Fig. 3. Kaplan-Meier estimates of overall survival according to docetaxel era (A) and the usage of docetaxel as first-line or second-line 
chemotherapy (B). (A) The patients after docetaxel era (after 2004) showed significantly longer overall survival (P=0.001; hazard ratio 
[HR], 0.65; 95% confidence interval [CI], 0.52 to 0.83). (B) The overall survival was longer in patients treated with docetaxel chemo-
therapy as second-line chemotherapy than in the patients treated with docetaxel chemotherapy as first-line chemotherapy. 
(P=0.002; HR, 0.60; 95% CI, 0.43 to 0.83).  
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increased according to the PSA response rate (not shown). 
 The emergence of docetaxel as an effective therapy, and the 
development of a new generation of agents for patients with 
CRPC have altered the treatment paradigm for this patient 
population. The Korean FDA also approved docetaxel for the 
treatment of CRPC in 2005. Therefore, docetaxel is actively be-
ing administrated to many patients throughout Korea. Joung 
et al. [16] reported the first results for the efficacy of docetaxel 
in Korean patients. They included patients with progressive 
disease despite prior chemotherapy; i.e., mitoxantrone-resis-
tant and estramustine resistant cases. That study compared 
the efficacy of docetaxel chemotherapy in Korean patients 
with hormone refractory prostate cancer between first- and 
second-line docetaxel. PSA response was more common 
in the first-line group, but this was not statistically different. 
However, the first-line group showed a longer time to PSA 
progression (4 months vs. 2 months, P = 0.015) and survival 
(17 months vs. 10 months, P = 0.037) than the second-line 
group did. At our institution, we recently reported the efficacy 
and safety of docetaxel plus prednisolone chemotherapy for 
metastatic hormone-refractory prostate adenocarcinoma [17]. 
In that study, a PSA response was seen in 51% of 63 evaluable 
patients at 12 weeks, maximal PSA decline ≥ 50% in 59% of 
70 evaluable patients. Tumor response was evaluated in 13 
patients, 4 patients achieved partial response, and 5 patients 
had stable disease with a response rate of 31%. Median over-
all survival was 22.8 months (95% CI, 16.6 to 29.1).
 It is well known that chemotherapy with docetaxel is cur-
rently the standard first-line cytotoxic treatment in CRPC. The 
clinical efficacy of docetaxel-based chemotherapy admin-
istered three times a week in patients with CRPC has been 
demonstrated in two randomized phase III trials (TAX-327 
study; SWOG99-16 study). The results showed a median sur-
vival benefit of 2 to 3 months compared with mitoxantrone 
and prednisone [5,6,18,19]. Recently, some studies reported 
that docetaxel rechallenge showed preserved antitumor activ-
ity and tumor response in first-line chemotherapy. Docetaxel 
has been suggested as an indicator for activity of docetaxel 
rechallenges [20-22]. Heck et al. [22] reported that in first-line 
docetaxel chemotherapy, 36 patients (82%) achieved a reduc-
tion in PSA level of ≥ 50%. In docetaxel chemotherapy rechal-
lenge, 10 patients (28%) responded with a reduction of ≥ 50% 
for the second time. The median (95% CI) PSA-progression 
free survival was 5.9 months (95% CI, 3.5 to 6.8), and the me-
dian overall survival was 21.8 months (95% CI, 19.9 to 23.7) 
at docetaxel rechallenge. A few studies have examined the 
outcomes of docetaxel chemotherapy in Asian countries, es-
pecially as a second-line treatment [23,24]. In our study, the 
PSA response rate ( > 50%) of docetaxel chemotherapy as a 
second-line treatment was 45%. The first study of a docetaxel 
rechallenge by Eymard et al. [7] reported a similar PSA re-
sponse rate (48%) with manageable toxicity. In our study, 
we did not show the toxicity of docetaxel in second-line 
chemotherapy, but several studies of second-line or rechal-
lenge docetaxel chemotherapy reported that toxicities were 
tolerable. Notably, Di Lorenz et al. [9] reported that the side 
effects were moderate, and the main hematological grade 3 
to 4 toxicities were neutropenia in 24.5%, thrombocytopenia 
in 11.1%, and anemia in 6.7% of patients. The main nonhe-
matological grades 3 to 4 toxicities were nausea/vomiting and 
hypertension in 6.6% and 6.6% of patients, respectively. The 
authors concluded that docetaxel rechallenge preserved anti-
tumor activity and was well tolerated in a selected population 
of pretreated patients with CRPC.
 Two large-scale randomized phase III trials recently tested 
the efficacy of new drugs as a second-line treatment after 
docetaxel failure: cabazitaxel, a new taxane that led to bet-
ter survival than mitoxantrone [4]; and Abiraterone, a new 
CYP17 inhibitor that was superior to placebo in terms of sur-
vival [3]. In 2010, phase III data in the TROPIC trial of cabazi-
taxel-based chemotherapy, 755 patients were randomized to 
receive either cabazitaxel 25 mg/m2 every three weeks plus 
prednisone or mitoxantrone 12 mg/m2 every three weeks 
plus prednisone. Eighteen patients in each arm received up 
to 10 cycles of treatment. OS (the primary end-point) was 
significantly longer in the cabazitaxel arm (15.1 months) than 
in the control arm (12.7 months) (HR, 0.70; 95% CI, 0.59 to 
0.83). Subgroup analysis showed a benefit even in heavily 
pretreated patients. Interestingly, in our study, the median 
overall survival was longer in patients treated with docetaxel 
chemotherapy as second-line chemotherapy than in the 
patients treated with docetaxel chemotherapy as first-line 
chemotherapy. However, the comparison analysis between 
baseline patient characteristics showed that patients with 
docetaxel chemotherapy as second-line chemotherapy had 
good prognosis factors, such as higher levels of hemoglobin 
and lower Gleason scores at initial diagnosis (not shown). We 
were impressed that docetaxel chemotherapy as second-line 
chemotherapy was more effective than the use of docetaxel 
administered to the chemo-naïve patients. We will further 
analyze this result in a future study with a larger population 
sample.
 One limitation of the present study is its retrospective 
design of PSA response criteria. A second limitation is that 
the first-line therapy for CRPC patients was determined at a 
physician’s discretion. Heterogeneous patients that did not 
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satisfy the inclusion criteria of the new CPRC definition (cas-
trate serum levels of testosterone [testosterone < 50 ng/dL], 
antiandrogen withdrawal for at least four weeks for flutamide 
and for at least six weeks for bicalutamide) were included in 
this study because these patients were treated before the con-
cept of CRPC was established. Nevertheless, the merits of the 
present study are that it analyzes a large cohort Koreans. The 
relatively few existing studies used small cohorts to examine 
the outcomes of chemotherapy in Asian countries.
 In conclusion, doxetacel showed superior PSA response 
rates compared to other agents as second-line chemotherapy 
in Korean CRPC patients. If docetaxel is not used as first-line 
chemotherapy and new agents is not available for therapy in 
CRPC patients, docetaxel could be considered a second-line 
chemotherapy in CRPC. Nevertheless, these retrospective 
data need confirmation in future prospective studies.
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